Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy (ATTR-ACT)

Clinical Trial ID NCT01994889

Rank	Title	Journal	Year	PubWeight™‹?›
1	Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.	Heart Fail Rev	2015	0.89
2	A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis.	Neurol Ther	2015	0.83
3	Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).	Amyloid	2015	0.81
4	Evolving landscape in the management of transthyretin amyloidosis.	Ann Med	2015	0.80
5	Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure.	Front Cardiovasc Med	2015	0.79
6	Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.	Neurol Ther	2016	0.77
7	Serial scanning with technetium pyrophosphate ((99m)Tc-PYP) in advanced ATTR cardiac amyloidosis.	J Nucl Cardiol	2015	0.76
8	Transthyretin Cardiac Amyloidosis in Older Americans.	J Card Fail	2016	0.75
9	Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.	J Cardiovasc Transl Res	2015	0.75